首页 > 最新文献

Ophthalmology and Therapy最新文献

英文 中文
Digital Physiotherapeutic Vision-Specific Training System for Patients with Diabetic Retinopathy: A Propensity Score-Matched Retrospective Cohort Study. 糖尿病视网膜病变患者的数字物理治疗视觉特异性训练系统:倾向评分匹配的回顾性队列研究。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-29 DOI: 10.1007/s40123-025-01283-z
Lisha Ni, Qiuju Zhou, Minghua Fan, Zihui Liu, Shengdi Lu, Yun Shen

Introduction: Diabetic retinopathy (DR) often causes vision loss and functional impairment. Standard low vision rehabilitation improves visual function but many patients cannot access it because of cost, travel, and limited specialist availability. We aimed to compare a home-based digital vision rehabilitation program to standard in-clinic rehabilitation in patients with DR.

Methods: We conducted a retrospective matched cohort study at a tertiary eye center in China. Adults with moderate to severe visual impairment from DR were included. A total of 380 patients were analyzed after 1:1 propensity score matching (190 per group). One group underwent a 12-week home-based digital physiotherapeutic vision training program delivered via a mobile app with daily exercises and weekly telehealth supervision, while the other group received standard in-person low vision rehabilitation over 12 weeks. The primary outcome was change in visual functional status measured by the Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 (VA LV VFQ-48). Secondary outcomes included visual acuity, vision-related quality of life, depressive symptoms, mobility, metabolic control, and cost. Outcomes were assessed at baseline, 12, 24, and 48 weeks.

Results: Both the home-based digital training and standard in-clinic rehabilitation groups achieved substantial improvements in vision-specific functional status over 48 weeks. VFQ-48 scores increased by 22-26 points in each group, indicating clinically meaningful gains, and the digital program's improvement was comparable to standard care (demonstrating non-inferiority for the primary outcome). All secondary outcomes improved comparably in both groups, with no significant between-group differences. The digital intervention cost 7791 Chinese yuan (CNY) per patient over 48 weeks compared to 10,305 CNY with standard care, providing a net savings of 2514 CNY per patient. Both approaches were well tolerated, with no major safety concerns.

Conclusions: Home-based digital rehabilitation was non-inferior to standard in-clinic rehabilitation in improving functional vision, while substantially reducing costs and maintaining safety. These findings support implementing home-based or hybrid telerehabilitation models to broaden access to vision rehabilitation services.

Level of evidence: Level III retrospective cohort study.

糖尿病性视网膜病变(DR)常导致视力丧失和功能损害。标准的低视力康复可以改善视力功能,但由于费用、旅行和专科医生有限,许多患者无法获得这种治疗。我们的目的是比较以家庭为基础的数字视力康复计划与dr患者的标准临床康复。方法:我们在中国一家三级眼科中心进行了一项回顾性匹配队列研究。患有中度至重度视力障碍的成人被纳入研究对象。按1:1的倾向评分匹配(每组190例),共分析380例患者。其中一组接受了为期12周的家庭数字物理治疗视力训练计划,该计划通过移动应用程序提供,每天进行练习,每周进行远程医疗监督,而另一组接受了为期12周的标准面对面低视力康复。主要结果是通过退伍军人事务低视力视觉功能问卷-48 (VA LV VFQ-48)测量视觉功能状态的变化。次要结局包括视力、视觉相关生活质量、抑郁症状、活动能力、代谢控制和费用。在基线、12周、24周和48周时评估结果。结果:基于家庭的数字训练和标准的临床康复组在48周内都取得了显著的视力特异性功能状态改善。VFQ-48评分每组提高22-26分,表明临床有意义的收益,数字程序的改善与标准治疗相当(证明主要结局的非劣效性)。两组的所有次要结局均有显著改善,组间无显著差异。数字干预在48周内每位患者的成本为7791元人民币,而标准治疗为10305元人民币,每位患者净节省2514元人民币。两种方法的耐受性都很好,没有重大的安全问题。结论:基于家庭的数字康复在改善功能视力方面不逊色于临床标准康复,同时大大降低了成本并保持了安全性。这些发现支持实施基于家庭或混合远程康复模式,以扩大获得视力康复服务的机会。证据等级:III级回顾性队列研究。
{"title":"Digital Physiotherapeutic Vision-Specific Training System for Patients with Diabetic Retinopathy: A Propensity Score-Matched Retrospective Cohort Study.","authors":"Lisha Ni, Qiuju Zhou, Minghua Fan, Zihui Liu, Shengdi Lu, Yun Shen","doi":"10.1007/s40123-025-01283-z","DOIUrl":"10.1007/s40123-025-01283-z","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic retinopathy (DR) often causes vision loss and functional impairment. Standard low vision rehabilitation improves visual function but many patients cannot access it because of cost, travel, and limited specialist availability. We aimed to compare a home-based digital vision rehabilitation program to standard in-clinic rehabilitation in patients with DR.</p><p><strong>Methods: </strong>We conducted a retrospective matched cohort study at a tertiary eye center in China. Adults with moderate to severe visual impairment from DR were included. A total of 380 patients were analyzed after 1:1 propensity score matching (190 per group). One group underwent a 12-week home-based digital physiotherapeutic vision training program delivered via a mobile app with daily exercises and weekly telehealth supervision, while the other group received standard in-person low vision rehabilitation over 12 weeks. The primary outcome was change in visual functional status measured by the Veterans Affairs Low-Vision Visual Functioning Questionnaire-48 (VA LV VFQ-48). Secondary outcomes included visual acuity, vision-related quality of life, depressive symptoms, mobility, metabolic control, and cost. Outcomes were assessed at baseline, 12, 24, and 48 weeks.</p><p><strong>Results: </strong>Both the home-based digital training and standard in-clinic rehabilitation groups achieved substantial improvements in vision-specific functional status over 48 weeks. VFQ-48 scores increased by 22-26 points in each group, indicating clinically meaningful gains, and the digital program's improvement was comparable to standard care (demonstrating non-inferiority for the primary outcome). All secondary outcomes improved comparably in both groups, with no significant between-group differences. The digital intervention cost 7791 Chinese yuan (CNY) per patient over 48 weeks compared to 10,305 CNY with standard care, providing a net savings of 2514 CNY per patient. Both approaches were well tolerated, with no major safety concerns.</p><p><strong>Conclusions: </strong>Home-based digital rehabilitation was non-inferior to standard in-clinic rehabilitation in improving functional vision, while substantially reducing costs and maintaining safety. These findings support implementing home-based or hybrid telerehabilitation models to broaden access to vision rehabilitation services.</p><p><strong>Level of evidence: </strong>Level III retrospective cohort study.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"373-391"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration. B族维生素在预防老年性黄斑变性发生和发展中的作用。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-07 DOI: 10.1007/s40123-025-01281-1
Julie Poteet, Cecelia Koetting, Priya S Vakharia

No current treatments are curative for age-related macular degeneration (AMD), and preventing disease progression is challenging. Dietary factors play a role in the course of macular degeneration, and management of AMD commonly includes nutraceuticals (e.g., supplementation with a combination of antioxidant vitamins and minerals). This commentary summarizes the existing literature, emerging evidence, and upcoming research on the role of B vitamins in both preventing the development of AMD and slowing its progression.

目前尚无治疗老年性黄斑变性(AMD)的方法,预防疾病进展具有挑战性。饮食因素在黄斑变性的过程中起作用,AMD的治疗通常包括营养药品(例如,补充抗氧化维生素和矿物质的组合)。这篇评论总结了现有的文献,新出现的证据,以及关于B族维生素在预防AMD发展和减缓其进展中的作用的未来研究。
{"title":"Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration.","authors":"Julie Poteet, Cecelia Koetting, Priya S Vakharia","doi":"10.1007/s40123-025-01281-1","DOIUrl":"10.1007/s40123-025-01281-1","url":null,"abstract":"<p><p>No current treatments are curative for age-related macular degeneration (AMD), and preventing disease progression is challenging. Dietary factors play a role in the course of macular degeneration, and management of AMD commonly includes nutraceuticals (e.g., supplementation with a combination of antioxidant vitamins and minerals). This commentary summarizes the existing literature, emerging evidence, and upcoming research on the role of B vitamins in both preventing the development of AMD and slowing its progression.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Subjective Visual Experiences During Intraocular Surgery and Intravitreal Injection Among Uveitis Patients at a Tertiary Eye Hospital: A Cross-Sectional Observational Study. 评价三级眼科医院葡萄膜炎患者眼内手术和玻璃体注射期间的主观视觉体验:一项横断面观察研究。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-06 DOI: 10.1007/s40123-025-01264-2
Sivaraman Bala Murugan, Sunil Kumar, Bharat Gurnani, Kirandeep Kaur

Introduction: Patients frequently report visual sensations during ophthalmic surgery; however, data in uveitic eyes remain limited. Patients with Uveitis  represent a unique population group because of the chronic inflammatory course, systemic associations, and prolonged pharmacologic exposure, which may influence intraoperative perception and anxiety. This study aimed to characterize the nature and impact of intraoperative subjective visual experiences in patients with uveitis undergoing intraocular surgery or intravitreal injection and to evaluate the association of these experiences with uveitic activity, preoperative anxiety, and intraoperative physiological fluctuations.

Methods: This prospective cross-sectional observational study was conducted at a tertiary eye care hospital between June 2022 and July 2023. Seventy-six patients with uveitis undergoing anterior segment surgery, posterior segment surgery, or intravitreal injection were enrolled. Patients younger than 18 years, those requiring general anaesthesia, or with psychiatric/systemic disorders affecting perception were excluded. Demographic variables, uveitis type, systemic history, and visual acuity were recorded. Preoperative anxiety was assessed using the Amsterdam Preoperative Anxiety and Information Scale (APAIS). Intraoperative visual phenomena were evaluated postoperatively using a standardized questionnaire, while vital parameters (blood pressure, pulse rate, and SpO2) were monitored throughout surgery.

Results: Among 76 patients (mean age 56 years; 48.7% male, 51.3% female), 60.5% underwent anterior segment surgery, 17.1% posterior segment surgery, and 22.3% intravitreal injections. All retained light perception intraoperatively. Common experiences included seeing colours (76.1% anterior; 61.5% posterior; 41.2% intravitreal), floaters (63%, 23%, 64.7%, respectively), and flashes (43.4%, 61.5%, 23.5%). Frightening perceptions occurred in 26.3% overall, significantly more in male patients (P = 0.008) and those with better preoperative visual acuity (P = 0.014). Notable intraoperative fluctuations were observed in systolic/diastolic blood pressure and pulse rate.

Conclusion: Patients with uveitis consistently experience intraoperative visual sensations irrespective of disease activity or surgical type. The occurrence of fear underscores the need for structured preoperative counselling, tailored anaesthetic management, and vigilant systemic monitoring to enhance patient comfort and surgical safety.

Trial registration no: CTRI/2022/07/043763.

患者在眼科手术中经常报告视觉感觉;然而,有关黄斑眼的资料仍然有限。葡萄膜炎患者是一个独特的群体,因为慢性炎症过程、系统性关联和长期的药物暴露,可能会影响术中感知和焦虑。本研究旨在描述接受眼内手术或玻璃体注射的葡萄膜炎患者术中主观视觉体验的性质和影响,并评估这些体验与葡萄膜活动、术前焦虑和术中生理波动的关系。方法:本前瞻性横断面观察性研究于2022年6月至2023年7月在一家三级眼科医院进行。76例接受前段手术、后段手术或玻璃体内注射的葡萄膜炎患者被纳入研究。年龄小于18岁、需要全身麻醉或患有影响感知的精神/全身疾病的患者被排除在外。记录人口统计学变量、葡萄膜炎类型、系统病史和视力。术前焦虑评估采用阿姆斯特丹术前焦虑与信息量表(APAIS)。采用标准化问卷评估术中视觉现象,同时在整个手术过程中监测重要参数(血压、脉搏率和SpO2)。结果:76例患者(平均年龄56岁,男性48.7%,女性51.3%)中,前段手术占60.5%,后段手术占17.1%,玻璃体内注射占22.3%。术中所有患者均保留光感。常见的体验包括看到颜色(76.1%前视、61.5%后视、41.2%玻璃体内)、飞蚊(分别为63%、23%、64.7%)和闪光(43.4%、61.5%、23.5%)。总发生率为26.3%,其中男性患者较多(P = 0.008),术前视力较好的患者较多(P = 0.014)。术中观察到明显的收缩压/舒张压和脉搏波动。结论:与疾病活动或手术类型无关,葡萄膜炎患者术中视觉感觉一致。恐惧的发生强调了有必要进行结构化的术前咨询、量身定制的麻醉管理和警惕的系统监测,以提高患者的舒适度和手术安全性。试验注册号:CTRI/2022/07/043763。
{"title":"Assessment of Subjective Visual Experiences During Intraocular Surgery and Intravitreal Injection Among Uveitis Patients at a Tertiary Eye Hospital: A Cross-Sectional Observational Study.","authors":"Sivaraman Bala Murugan, Sunil Kumar, Bharat Gurnani, Kirandeep Kaur","doi":"10.1007/s40123-025-01264-2","DOIUrl":"10.1007/s40123-025-01264-2","url":null,"abstract":"<p><strong>Introduction: </strong>Patients frequently report visual sensations during ophthalmic surgery; however, data in uveitic eyes remain limited. Patients with Uveitis  represent a unique population group because of the chronic inflammatory course, systemic associations, and prolonged pharmacologic exposure, which may influence intraoperative perception and anxiety. This study aimed to characterize the nature and impact of intraoperative subjective visual experiences in patients with uveitis undergoing intraocular surgery or intravitreal injection and to evaluate the association of these experiences with uveitic activity, preoperative anxiety, and intraoperative physiological fluctuations.</p><p><strong>Methods: </strong>This prospective cross-sectional observational study was conducted at a tertiary eye care hospital between June 2022 and July 2023. Seventy-six patients with uveitis undergoing anterior segment surgery, posterior segment surgery, or intravitreal injection were enrolled. Patients younger than 18 years, those requiring general anaesthesia, or with psychiatric/systemic disorders affecting perception were excluded. Demographic variables, uveitis type, systemic history, and visual acuity were recorded. Preoperative anxiety was assessed using the Amsterdam Preoperative Anxiety and Information Scale (APAIS). Intraoperative visual phenomena were evaluated postoperatively using a standardized questionnaire, while vital parameters (blood pressure, pulse rate, and SpO<sub>2</sub>) were monitored throughout surgery.</p><p><strong>Results: </strong>Among 76 patients (mean age 56 years; 48.7% male, 51.3% female), 60.5% underwent anterior segment surgery, 17.1% posterior segment surgery, and 22.3% intravitreal injections. All retained light perception intraoperatively. Common experiences included seeing colours (76.1% anterior; 61.5% posterior; 41.2% intravitreal), floaters (63%, 23%, 64.7%, respectively), and flashes (43.4%, 61.5%, 23.5%). Frightening perceptions occurred in 26.3% overall, significantly more in male patients (P = 0.008) and those with better preoperative visual acuity (P = 0.014). Notable intraoperative fluctuations were observed in systolic/diastolic blood pressure and pulse rate.</p><p><strong>Conclusion: </strong>Patients with uveitis consistently experience intraoperative visual sensations irrespective of disease activity or surgical type. The occurrence of fear underscores the need for structured preoperative counselling, tailored anaesthetic management, and vigilant systemic monitoring to enhance patient comfort and surgical safety.</p><p><strong>Trial registration no: </strong>CTRI/2022/07/043763.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"173-191"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Volumes of Choroidal Nevi on Widefield Optical Coherence Tomography Compared to Calculations Based on Ultrasound Measurements. 宽视场光学相干层析成像的脉络膜痣体积与基于超声测量的计算比较。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-20 DOI: 10.1007/s40123-025-01271-3
Judith E Kreminger, Reinhard Told, Elena Zafeiri, Adrian Reumueller, Roman Dunavoelgyi, Stefan Sacu

Introduction: This study aimed to evaluate choroidal nevi (CN) volume as assessed by widefield optical coherence tomography (WF-OCT) and by ultrasound (US)-based mathematical approximations.

Methods: In a prospective, exploratory study, CN of consecutive patients were imaged with WF-OCT (VG 200D, Intalight Inc., San Jose, California, USA) and US (Quantel Absolu, Cournon, D'Auvergne Cedex, France). Volume was assessed by CN annotation on 64 B-scans on WF-OCT and two approximations based on US measurements (thickness, largest and perpendicular basal diameter (LBD; PBD)): (a) π/6 × thickness × LBD × PBD and (b) 2π/3 × [(LBD + PBD)/4]2 × thickness.

Results: Eighteen nevi of 18 patients were included in the study. Mean volume evaluated on WF-OCT was 15.1 ± 24.1 mm3. US approximations resulted in (a) 23.0 ± 35.0 mm3 and (b) 23.5 ± 35.5 mm3. Intraclass correlation coefficients showed very good agreement between WF-OCT and US measurements (a) of 0.947 (CI 0.860-0.980) and (b) of 0.945 (CI 0.853-0.979). Stepwise backward elimination multivariable linear regression showed an association between difference of volume measurements and lesion thickness and LBD for approximations (a) and (b).

Conclusion: WF-OCT and US-based approximations show good interdevice reliability for CN volume in this exploratory study. Thickness and LBD have significant impact on discrepancy of volume measurements with a tendency that small CN are underestimated and large CN are overestimated with US. This potentially limits interchangeable use of US and WF-OCT.

本研究旨在通过广角光学相干断层扫描(WF-OCT)和基于超声(US)的数学近似来评估脉络膜痣(CN)的体积。方法:在一项前瞻性、探索性研究中,连续使用WF-OCT (VG 200D, Intalight Inc., San Jose, California, USA)和US (Quantel Absolu, Cournon, D'Auvergne Cedex, France)对患者的CN进行成像。通过对64张WF-OCT b扫描的CN注释和基于US测量的两个近似(厚度,最大和垂直基底直径(LBD; PBD))评估体积:(a) π/6 ×厚度× LBD × PBD和(b) 2π/3 × [(LBD + PBD)/4]2 ×厚度。结果:18例患者的18个痣被纳入研究。WF-OCT平均体积为15.1±24.1 mm3。US近似结果为(a) 23.0±35.0 mm3和(b) 23.5±35.5 mm3。类内相关系数显示WF-OCT和US测量值非常吻合(a) 0.947 (CI 0.860-0.980)和(b) 0.945 (CI 0.853-0.979)。逐步后向消除多变量线性回归显示,在近似(a)和(b)中,体积测量值的差异、病变厚度和LBD之间存在关联。结论:在这项探索性研究中,WF-OCT和基于美国的近似显示出良好的设备间CN体积可靠性。厚度和LBD对体积测量差异有显著影响,且US有低估小CN和高估大CN的趋势。这可能会限制US和WF-OCT的可互换使用。
{"title":"Volumes of Choroidal Nevi on Widefield Optical Coherence Tomography Compared to Calculations Based on Ultrasound Measurements.","authors":"Judith E Kreminger, Reinhard Told, Elena Zafeiri, Adrian Reumueller, Roman Dunavoelgyi, Stefan Sacu","doi":"10.1007/s40123-025-01271-3","DOIUrl":"10.1007/s40123-025-01271-3","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate choroidal nevi (CN) volume as assessed by widefield optical coherence tomography (WF-OCT) and by ultrasound (US)-based mathematical approximations.</p><p><strong>Methods: </strong>In a prospective, exploratory study, CN of consecutive patients were imaged with WF-OCT (VG 200D, Intalight Inc., San Jose, California, USA) and US (Quantel Absolu, Cournon, D'Auvergne Cedex, France). Volume was assessed by CN annotation on 64 B-scans on WF-OCT and two approximations based on US measurements (thickness, largest and perpendicular basal diameter (LBD; PBD)): (a) π/6 × thickness × LBD × PBD and (b) 2π/3 × [(LBD + PBD)/4]<sup>2</sup> × thickness.</p><p><strong>Results: </strong>Eighteen nevi of 18 patients were included in the study. Mean volume evaluated on WF-OCT was 15.1 ± 24.1 mm<sup>3</sup>. US approximations resulted in (a) 23.0 ± 35.0 mm<sup>3</sup> and (b) 23.5 ± 35.5 mm<sup>3</sup>. Intraclass correlation coefficients showed very good agreement between WF-OCT and US measurements (a) of 0.947 (CI 0.860-0.980) and (b) of 0.945 (CI 0.853-0.979). Stepwise backward elimination multivariable linear regression showed an association between difference of volume measurements and lesion thickness and LBD for approximations (a) and (b).</p><p><strong>Conclusion: </strong>WF-OCT and US-based approximations show good interdevice reliability for CN volume in this exploratory study. Thickness and LBD have significant impact on discrepancy of volume measurements with a tendency that small CN are underestimated and large CN are overestimated with US. This potentially limits interchangeable use of US and WF-OCT.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"351-359"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145564978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Individualized and Adaptive Vision Training versus 6 hours of Patching in Children with Residual Amblyopia: A Randomized Clinical Trial. 个体化和适应性视觉训练与6小时补片对残弱视儿童的影响:一项随机临床试验
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-09 DOI: 10.1007/s40123-025-01287-9
Junli Yuan, Yuanyuan Chen, Lu Wang, Meiping Xu, Na Liao, Zhiyue Dai, Hui Chen, Binjun Zhang, Jinling Xu, Minghui Wan, Suzhong Xu, Yuwen Wang, Xiaolin Huang, Fuhao Zheng, Pingping Huang, Jie Chen, Chang-Bing Huang, Fang-Fang Yan, Xinping Yu, Huanyun Yu

Introduction: Despite refractive correction and patching, some patients have residual amblyopia. In the current study, we compared the effectiveness of daily 6-hours (6-h) intensive patching and a newly developed individualized and adaptive vision training (iAVT) protocol for residual amblyopia in children.

Methods: In a randomized clinical trial, 60 children aged 4 to under 11 years with residual amblyopia and visual acuity ranging from 0.2 to 0.8 logarithm of the minimum angle of resolution (logMAR) were assigned to receive either 50 sessions of iAVT training or 6 h of daily patching for 10 weeks.

Results: Visual acuity in the amblyopic eye improved more in the iAVT group than in the extended patching group (0.13 versus 0.07 logMAR; 95% confidence interval (CI) 0.010-0.100; p = 0.017) over 10 weeks. At 2 weeks, the iAVT group also showed a faster improvement compared with the patching group (0.09 versus 0.06 logMAR; 95% CI -0.004 to 0.067; p = 0.076). Meanwhile, no significant between-group difference was found in the area under the log contrast sensitivity function (AULCSF) change. However, the AULCSF of the iAVT group showed a marginally significant within-group improvement from base to week 10 (0.78 versus 0.89; 95% CI -0.225 to 0.001; p = 0.056), while no significant change was observed in the patching group. The iAVT group also reported higher quality-of-life scores after treatment, as monitored by the Pediatric Eye Questionnaire.

Conclusions: The iAVT provided a faster and more effective treatment for residual amblyopia compared with 6-h patching within the 10-week treatment period. These results suggest that iAVT may be an important new approach to treating residual amblyopia.

Trail registration: Chinese Clinical Trial Registry, ChiCTR2300075594. Registered on 8 September 2023-retrospectively registered.

尽管有屈光矫正和配片,一些患者仍有残余弱视。在目前的研究中,我们比较了每天6小时(6小时)强化补片和新开发的个性化和适应性视觉训练(iAVT)方案对儿童残余弱视的有效性。方法:在一项随机临床试验中,60名年龄在4至11岁以下的残弱视儿童,视力范围为最小分辨角(logMAR)的0.2至0.8对数,被分配接受50次iAVT训练或每天6小时的贴片,为期10周。结果:iAVT组弱视眼的视力改善程度高于扩展贴片组(0.13 vs 0.07 logMAR; 95%可信区间(CI) 0.010-0.100;P = 0.017)。在2周时,iAVT组也比贴片组表现出更快的改善(0.09对0.06 logMAR; 95% CI -0.004至0.067;p = 0.076)。同时,对数对比敏感度函数(AULCSF)变化下的面积组间无显著差异。然而,从基础到第10周,iAVT组的AULCSF在组内略有显著改善(0.78 vs 0.89; 95% CI -0.225 to 0.001; p = 0.056),而在贴片组中未观察到显著变化。iAVT组也报告了治疗后更高的生活质量评分,这是由儿科眼科问卷监测的。结论:在10周的治疗期内,iAVT比6小时补片治疗残余弱视更快、更有效。这些结果提示iAVT可能是治疗残余弱视的重要新方法。试验注册:中国临床试验注册中心,ChiCTR2300075594。于2023年9月8日注册,已追溯注册。
{"title":"Effect of Individualized and Adaptive Vision Training versus 6 hours of Patching in Children with Residual Amblyopia: A Randomized Clinical Trial.","authors":"Junli Yuan, Yuanyuan Chen, Lu Wang, Meiping Xu, Na Liao, Zhiyue Dai, Hui Chen, Binjun Zhang, Jinling Xu, Minghui Wan, Suzhong Xu, Yuwen Wang, Xiaolin Huang, Fuhao Zheng, Pingping Huang, Jie Chen, Chang-Bing Huang, Fang-Fang Yan, Xinping Yu, Huanyun Yu","doi":"10.1007/s40123-025-01287-9","DOIUrl":"10.1007/s40123-025-01287-9","url":null,"abstract":"<p><strong>Introduction: </strong>Despite refractive correction and patching, some patients have residual amblyopia. In the current study, we compared the effectiveness of daily 6-hours (6-h) intensive patching and a newly developed individualized and adaptive vision training (iAVT) protocol for residual amblyopia in children.</p><p><strong>Methods: </strong>In a randomized clinical trial, 60 children aged 4 to under 11 years with residual amblyopia and visual acuity ranging from 0.2 to 0.8 logarithm of the minimum angle of resolution (logMAR) were assigned to receive either 50 sessions of iAVT training or 6 h of daily patching for 10 weeks.</p><p><strong>Results: </strong>Visual acuity in the amblyopic eye improved more in the iAVT group than in the extended patching group (0.13 versus 0.07 logMAR; 95% confidence interval (CI) 0.010-0.100; p = 0.017) over 10 weeks. At 2 weeks, the iAVT group also showed a faster improvement compared with the patching group (0.09 versus 0.06 logMAR; 95% CI -0.004 to 0.067; p = 0.076). Meanwhile, no significant between-group difference was found in the area under the log contrast sensitivity function (AULCSF) change. However, the AULCSF of the iAVT group showed a marginally significant within-group improvement from base to week 10 (0.78 versus 0.89; 95% CI -0.225 to 0.001; p = 0.056), while no significant change was observed in the patching group. The iAVT group also reported higher quality-of-life scores after treatment, as monitored by the Pediatric Eye Questionnaire.</p><p><strong>Conclusions: </strong>The iAVT provided a faster and more effective treatment for residual amblyopia compared with 6-h patching within the 10-week treatment period. These results suggest that iAVT may be an important new approach to treating residual amblyopia.</p><p><strong>Trail registration: </strong>Chinese Clinical Trial Registry, ChiCTR2300075594. Registered on 8 September 2023-retrospectively registered.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"443-456"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145708828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study. 更正:富氏营养不良患者DMEK后薄角膜的层析成像差异:一项病例对照研究。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 DOI: 10.1007/s40123-025-01293-x
Josep Torras-Sanvicens, Marc Figueras-Roca, Carlos Rocha-de-Losada, Inés Bourleau, Ariadna Garreta, Elena Millá-Griñó, Ricardo P Casaroli-Marano
{"title":"Correction: Tomographic Differences in Thin Corneas Following DMEK in Fuchs Dystrophy: A Case-Control Study.","authors":"Josep Torras-Sanvicens, Marc Figueras-Roca, Carlos Rocha-de-Losada, Inés Bourleau, Ariadna Garreta, Elena Millá-Griñó, Ricardo P Casaroli-Marano","doi":"10.1007/s40123-025-01293-x","DOIUrl":"10.1007/s40123-025-01293-x","url":null,"abstract":"","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"221"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corneal Sensitivity with the Non-contact Esthesiometer as Compared to the Cotton Wisp Test in Patients with Ocular Surface Diseases. 非接触式角膜感受器与棉线试验在眼表疾病患者角膜敏感度的比较
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-04 DOI: 10.1007/s40123-025-01284-y
Neslihan D Koseoglu, Luiz L Lamazales, Stephanie M Cox, Ana Balbuena-Pareja, Onur Olcucu, Pedram Hamrah

Introduction: Intact corneal sensation plays a vital role in maintaining ocular surface health. Various ocular surface pathologies can present with differing levels of decreased corneal sensation, while in some cases patients may instead experience heightened sensation. This study compared corneal sensitivity with the new quantitative non-contact esthesiometer (NCE, Brill, USA) and the conventional qualitative cotton wisp (CW) test in patients with ocular surface diseases (OSD).

Methods: A retrospective, cross-sectional study was conducted, including patients with OSDs, who had both CW and NCE test results available. Descriptive analysis of one eye per patient was performed to compare the distribution of patients according to NCE and CW responses.

Results: Of 139 eyes (n = 139 patients), 129 (92.8%) were CW+ and 10 eyes were CW- (7.2%). Among these, 111 eyes responded to levels 1-3 when assessed with NCE, with 38 (34.2%) responding to level 1, 45 (40.5%) to level 2, and 28 (25.2%) to level 3. However, of CW+ eyes, 10 (7.8%) responded to level 4 and 6 (4.7%) responded to level 5 of NCE, while 2 (1.6%) had no response to any NCE stimulation (i.e., level 6), indicating varying degrees of hyposensitivity not detected by CW. Of the 10 eyes (7.2%) that did not respond to CW (CW-), 3 responded to level 4, and one to level 5 of NCE, while 4 eyes (40.0%) failed to respond to NCE (level 6). Notably, two CW- patients responded to level 1 NCE, suggesting potential hypersensitivity. Results showed high sensitivity (98.2%, 95% CI 93.8-99.8%) but low specificity (30.8%, 95% CI 14.3-51.8%) of the CW test in patients with OSD when level 4 of NCE (i.e., levels 4, 5, and 6) was used as the cutoff for defining corneal hyposensitivity.

Conclusion: Our results demonstrate that the low specificity of the qualitative CW test, combined with a broad confidence interval, indicates a high likelihood of false-positive results. This suggests that a positive CW test may not reliably rule out hyposensitivity, underscoring the need for further evaluation in the setting of a positive CW test result.

完整的角膜感觉在维持眼表健康中起着至关重要的作用。不同的眼表病变可表现为不同程度的角膜感觉下降,而在某些情况下,患者可能会体验到增强的感觉。本研究比较了新型定量非接触感测仪(NCE, Brill, USA)和常规定性棉线(CW)试验对眼表疾病(OSD)患者角膜敏感度的影响。方法:回顾性、横断面研究,纳入有CW和NCE检测结果的osd患者。对每位患者进行一只眼的描述性分析,根据NCE和CW反应比较患者的分布。结果139只眼(n = 139例)中,CW+ 129只(92.8%),CW- 10只(7.2%)。其中111只眼睛在NCE评估时对1-3级有反应,38只(34.2%)对1级有反应,45只(40.5%)对2级有反应,28只(25.2%)对3级有反应。然而,在CW+眼中,10只(7.8%)对NCE 4级有反应,6只(4.7%)对NCE 5级有反应,而2只(1.6%)对任何NCE刺激都没有反应(即6级),表明CW未检测到不同程度的低敏感性。10只眼(7.2%)对CW (CW-)无反应,3只眼对NCE 4级有反应,1只眼对NCE 5级有反应,4只眼(40.0%)对NCE 6级无反应。值得注意的是,两名CW-患者对1级NCE有反应,提示潜在的过敏。结果显示,当使用4级NCE(即4、5、6级)作为定义角膜低敏感性的临界值时,OSD患者的CW检测灵敏度高(98.2%,95% CI 93.8-99.8%),但特异性低(30.8%,95% CI 14.3-51.8%)。结论:我们的结果表明,定性CW测试的低特异性,加上广泛的置信区间,表明假阳性结果的可能性很高。这表明,阳性连续波试验可能不能可靠地排除低敏感性,强调需要在阳性连续波试验结果的背景下进一步评估。
{"title":"Corneal Sensitivity with the Non-contact Esthesiometer as Compared to the Cotton Wisp Test in Patients with Ocular Surface Diseases.","authors":"Neslihan D Koseoglu, Luiz L Lamazales, Stephanie M Cox, Ana Balbuena-Pareja, Onur Olcucu, Pedram Hamrah","doi":"10.1007/s40123-025-01284-y","DOIUrl":"10.1007/s40123-025-01284-y","url":null,"abstract":"<p><strong>Introduction: </strong>Intact corneal sensation plays a vital role in maintaining ocular surface health. Various ocular surface pathologies can present with differing levels of decreased corneal sensation, while in some cases patients may instead experience heightened sensation. This study compared corneal sensitivity with the new quantitative non-contact esthesiometer (NCE, Brill, USA) and the conventional qualitative cotton wisp (CW) test in patients with ocular surface diseases (OSD).</p><p><strong>Methods: </strong>A retrospective, cross-sectional study was conducted, including patients with OSDs, who had both CW and NCE test results available. Descriptive analysis of one eye per patient was performed to compare the distribution of patients according to NCE and CW responses.</p><p><strong>Results: </strong>Of 139 eyes (n = 139 patients), 129 (92.8%) were CW+ and 10 eyes were CW- (7.2%). Among these, 111 eyes responded to levels 1-3 when assessed with NCE, with 38 (34.2%) responding to level 1, 45 (40.5%) to level 2, and 28 (25.2%) to level 3. However, of CW+ eyes, 10 (7.8%) responded to level 4 and 6 (4.7%) responded to level 5 of NCE, while 2 (1.6%) had no response to any NCE stimulation (i.e., level 6), indicating varying degrees of hyposensitivity not detected by CW. Of the 10 eyes (7.2%) that did not respond to CW (CW-), 3 responded to level 4, and one to level 5 of NCE, while 4 eyes (40.0%) failed to respond to NCE (level 6). Notably, two CW- patients responded to level 1 NCE, suggesting potential hypersensitivity. Results showed high sensitivity (98.2%, 95% CI 93.8-99.8%) but low specificity (30.8%, 95% CI 14.3-51.8%) of the CW test in patients with OSD when level 4 of NCE (i.e., levels 4, 5, and 6) was used as the cutoff for defining corneal hyposensitivity.</p><p><strong>Conclusion: </strong>Our results demonstrate that the low specificity of the qualitative CW test, combined with a broad confidence interval, indicates a high likelihood of false-positive results. This suggests that a positive CW test may not reliably rule out hyposensitivity, underscoring the need for further evaluation in the setting of a positive CW test result.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"403-414"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy, Repeatability, and Safety of Retreatment with Micropulse Cyclophotocoagulation in the Management of Glaucoma. 微脉冲光凝治疗青光眼的疗效、可重复性和安全性。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-10-31 DOI: 10.1007/s40123-025-01266-0
Ronald M P C de Crom, Stefani Kujovic-Aleksov, Carroll A B Webers, Tos T J M Berendschot, Henny J M Beckers

Introduction: This study investigated the effectiveness, repeatability, and safety of retreatments with micropulse transscleral cyclophotocoagulation (MP-TSCPC).

Methods: A retrospective cohort study was conducted on 76 eyes of patients with glaucoma who underwent standardized MP-TSCPC at the University Eye Clinic Maastricht between November 2016 and February 2019. Patients with at least one retreatment and a follow-up of 6 months or more were included and divided into four groups on the basis of their response to the primary treatment: nonresponder (NR), early attrition (EA), late attrition (LA), and enhancement (EH). Intraocular pressure (IOP) and IOP lowering medication use were recorded, and complications were assessed. Treatment success was defined as an IOP reduction of ≥ 20% compared with baseline or a decrease in the number of IOP-lowering medications with stable target IOP.

Results: Three months after retreatment, the NR, EA, LA, and EH groups experienced significant IOP reductions of 24.7%, 35.3%, 24.7%, and 28.2%, respectively. Significant medication reduction was observed only in the EH group. At the last follow-up, treatment success was achieved in 39.4% (NR), 33.3% (EA), 41.7% (LA), and 60.0% (EH) of the patients. Among patients receiving a second retreatment, the EH group demonstrated the most favorable and sustained outcomes. Early postoperative complications after retreatment (5.26%) were mild and reversible. A late complication of persistent hypotony developed in one patient (1.3%). Additional glaucoma surgery was required in 28.9% of the eyes.

Conclusions: Retreatment with micropulse TSCPC is a safe and effective option for (further) lowering IOP in patients with glaucoma. Especially patients who responded well to the primary treatment and patients who initially showed a good response but in whom the effect of the primary treatment has worn off have shown to be good candidates for retreatment. Repeatability and treatment success are most evident in initial responders and the primary benefit of retreatment is IOP reduction, with a less consistent effect on reducing IOP lowering medications.

本研究探讨了微脉冲经巩膜光凝治疗(MP-TSCPC)的有效性、可重复性和安全性。方法:对2016年11月至2019年2月期间在马斯特里赫特大学眼科诊所接受标准化MP-TSCPC治疗的76只青光眼患者进行回顾性队列研究。纳入至少一次再治疗并随访6个月或更长时间的患者,并根据其对主要治疗的反应分为四组:无反应(NR),早期消耗(EA),晚期消耗(LA)和增强(EH)。记录眼内压(IOP)和降低IOP的药物使用情况,并评估并发症。治疗成功定义为IOP较基线降低≥20%,或降低IOP药物的数量减少,目标IOP稳定。结果:再治疗3个月后,NR组、EA组、LA组和EH组眼压分别显著降低24.7%、35.3%、24.7%和28.2%。仅在EH组中观察到显著的药物减少。末次随访时,治疗成功率分别为39.4% (NR)、33.3% (EA)、41.7% (LA)和60.0% (EH)。在接受第二次再治疗的患者中,EH组表现出最有利和持续的结果。术后复治后早期并发症轻微且可逆(5.26%)。1例患者出现持续性低斜视的晚期并发症(1.3%)。28.9%的眼睛需要额外的青光眼手术。结论:微脉冲TSCPC治疗青光眼患者是一种安全有效的(进一步)降低IOP的方法。特别是对初次治疗反应良好的患者和最初表现出良好反应但初次治疗的效果已经消退的患者都是再治疗的良好候选者。可重复性和治疗成功在初始应答者中最为明显,再治疗的主要益处是降低IOP,减少降低IOP药物的效果不太一致。
{"title":"Efficacy, Repeatability, and Safety of Retreatment with Micropulse Cyclophotocoagulation in the Management of Glaucoma.","authors":"Ronald M P C de Crom, Stefani Kujovic-Aleksov, Carroll A B Webers, Tos T J M Berendschot, Henny J M Beckers","doi":"10.1007/s40123-025-01266-0","DOIUrl":"10.1007/s40123-025-01266-0","url":null,"abstract":"<p><strong>Introduction: </strong>This study investigated the effectiveness, repeatability, and safety of retreatments with micropulse transscleral cyclophotocoagulation (MP-TSCPC).</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 76 eyes of patients with glaucoma who underwent standardized MP-TSCPC at the University Eye Clinic Maastricht between November 2016 and February 2019. Patients with at least one retreatment and a follow-up of 6 months or more were included and divided into four groups on the basis of their response to the primary treatment: nonresponder (NR), early attrition (EA), late attrition (LA), and enhancement (EH). Intraocular pressure (IOP) and IOP lowering medication use were recorded, and complications were assessed. Treatment success was defined as an IOP reduction of ≥ 20% compared with baseline or a decrease in the number of IOP-lowering medications with stable target IOP.</p><p><strong>Results: </strong>Three months after retreatment, the NR, EA, LA, and EH groups experienced significant IOP reductions of 24.7%, 35.3%, 24.7%, and 28.2%, respectively. Significant medication reduction was observed only in the EH group. At the last follow-up, treatment success was achieved in 39.4% (NR), 33.3% (EA), 41.7% (LA), and 60.0% (EH) of the patients. Among patients receiving a second retreatment, the EH group demonstrated the most favorable and sustained outcomes. Early postoperative complications after retreatment (5.26%) were mild and reversible. A late complication of persistent hypotony developed in one patient (1.3%). Additional glaucoma surgery was required in 28.9% of the eyes.</p><p><strong>Conclusions: </strong>Retreatment with micropulse TSCPC is a safe and effective option for (further) lowering IOP in patients with glaucoma. Especially patients who responded well to the primary treatment and patients who initially showed a good response but in whom the effect of the primary treatment has worn off have shown to be good candidates for retreatment. Repeatability and treatment success are most evident in initial responders and the primary benefit of retreatment is IOP reduction, with a less consistent effect on reducing IOP lowering medications.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"155-172"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145422503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-Year Efficacy and Tolerance of Myofix Defocus Spectacles for Control of Myopia Progression. Myofix离焦眼镜控制近视进展的一年疗效和耐受性。
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-11-12 DOI: 10.1007/s40123-025-01270-4
Rafael Iribarren, Abel Szeps, Carlos Kotlik, Martin de Tomas, Gabriel Martin, Jos Rozema, Carla Lanca

Introduction: To report the 1-year efficacy of Myofix Defocus spectacles, designed to control the progression of myopia in childhood.

Methods: A total of 47 children with myopia aged 7-15 years were enrolled. Cycloplegic objective refraction (spherical equivalent refraction, SE) and axial length (AL) were measured at baseline, 6 months, and 12 months. Linear regression models were used to identify risk factors of 12-month changes in SE and AL. For comparison, two virtual control groups of children were included. Tolerance was assessed through a questionnaire at each follow-up visit.

Results: Of the initial cohort, 11 participants were lost to follow-up after 6 months due to reasons unrelated to lens design (77.1% retention rate). Over 12 months, the mean SE change in all eyes was - 0.21 ± 0.30 D, and AL change was 0.19 ± 0.13 mm. Progression was significantly different in participants who reported good compared to poor compliance (p < 0.001). At the 12-month follow-up, participants with good compliance had a mean SE progression of - 0.12 ± 0.25 D and a mean AL change of 0.17 ± 0.11 mm. In virtual controls, the mean annual SE progression was - 0.47 ± 0.36 D, and AL change was 0.26 ± 0.17 mm (both p < 0.001). In compliant participants, Myofix Defocus lens demonstrated a 75% reduction in SE and 37% reduction in AL compared to virtual controls.

Conclusions: After 1 year, Myofix Defocus spectacles slowed myopia progression in children, demonstrating comparable efficacy to other defocus-incorporated spectacle designs. Greater compliance resulted in better treatment effect. Further long-term studies are warranted to confirm these findings.

Trial registration: ClinicalTrials.gov identifier: NCT07092072. Registered retrospectively on July 29, 2025.

前言:报告Myofix离焦眼镜用于控制儿童近视发展的1年疗效。方法:选取47例7 ~ 15岁近视儿童。在基线、6个月和12个月时测量睫状体麻痹物镜折射(球面等效折射,SE)和轴长(AL)。使用线性回归模型确定12个月SE和AL变化的危险因素。为了进行比较,包括两个虚拟对照组的儿童。在每次随访时通过问卷评估耐受性。结果:在最初的队列中,有11名参与者在6个月后由于与晶状体设计无关的原因失去随访(77.1%的保留率)。12个月内,所有眼平均SE变化为- 0.21±0.30 D, AL变化为0.19±0.13 mm。结论:1年后,Myofix离焦眼镜减缓了儿童近视的进展,与其他离焦眼镜设计显示出相当的疗效。依从性越好,治疗效果越好。需要进一步的长期研究来证实这些发现。试验注册:ClinicalTrials.gov标识符:NCT07092072。于2025年7月29日追溯注册。
{"title":"One-Year Efficacy and Tolerance of Myofix Defocus Spectacles for Control of Myopia Progression.","authors":"Rafael Iribarren, Abel Szeps, Carlos Kotlik, Martin de Tomas, Gabriel Martin, Jos Rozema, Carla Lanca","doi":"10.1007/s40123-025-01270-4","DOIUrl":"10.1007/s40123-025-01270-4","url":null,"abstract":"<p><strong>Introduction: </strong>To report the 1-year efficacy of Myofix Defocus spectacles, designed to control the progression of myopia in childhood.</p><p><strong>Methods: </strong>A total of 47 children with myopia aged 7-15 years were enrolled. Cycloplegic objective refraction (spherical equivalent refraction, SE) and axial length (AL) were measured at baseline, 6 months, and 12 months. Linear regression models were used to identify risk factors of 12-month changes in SE and AL. For comparison, two virtual control groups of children were included. Tolerance was assessed through a questionnaire at each follow-up visit.</p><p><strong>Results: </strong>Of the initial cohort, 11 participants were lost to follow-up after 6 months due to reasons unrelated to lens design (77.1% retention rate). Over 12 months, the mean SE change in all eyes was - 0.21 ± 0.30 D, and AL change was 0.19 ± 0.13 mm. Progression was significantly different in participants who reported good compared to poor compliance (p < 0.001). At the 12-month follow-up, participants with good compliance had a mean SE progression of - 0.12 ± 0.25 D and a mean AL change of 0.17 ± 0.11 mm. In virtual controls, the mean annual SE progression was - 0.47 ± 0.36 D, and AL change was 0.26 ± 0.17 mm (both p < 0.001). In compliant participants, Myofix Defocus lens demonstrated a 75% reduction in SE and 37% reduction in AL compared to virtual controls.</p><p><strong>Conclusions: </strong>After 1 year, Myofix Defocus spectacles slowed myopia progression in children, demonstrating comparable efficacy to other defocus-incorporated spectacle designs. Greater compliance resulted in better treatment effect. Further long-term studies are warranted to confirm these findings.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT07092072. Registered retrospectively on July 29, 2025.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"253-271"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. 切换到Brolucizumab治疗难治性新生血管性年龄相关性黄斑变性后脉络膜厚度与脉络膜血流减少的显著相关性
IF 3.2 3区 医学 Q2 OPHTHALMOLOGY Pub Date : 2026-01-01 Epub Date: 2025-12-01 DOI: 10.1007/s40123-025-01279-9
Hirokazu Kojima, Ayana Yamashita, Yuki Nakano, Aki Booka, Yusuke Tatara, Takeyasu Yamada, Junichiro Akimitsu, Yukiko Miyoshi, Rie Osaka, Kiyoshi Suzuma

Introduction: Anti-vascular endothelial growth factor (VEGF) therapy suppresses neovascularization in neovascular age-related macular degeneration (nAMD) but may reduce ocular blood flow. However, its relationship with choroidal thickness remains unclear. This study evaluated 1-month outcomes after switching from intravitreal aflibercept or ranibizumab to intravitreal brolucizumab (IVBr) in patients with refractory nAMD.

Methods: This prospective, single-center study included 50 eyes of 50 patients with nAMD. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), choroidal vascularity index (CVI), choroidal stromal area (SA), choroidal luminal area (LA), optic nerve head (ONH) mean blur rate (MBR), and choroidal (CHOR) MBR were evaluated before and 1 month after switching to IVBr, with blood flow measured using laser speckle flowgraphy. Univariate analyses were performed to identify potential predictors of changes in CHOR-MBR, and variables with P < 0.1 were entered into a multiple regression model.

Results: BCVA was maintained. CRT decreased from 371.6 ± 118.7 to 288.8 ± 89.7 µm (P < 0.001). SFCT decreased from 231.9 ± 118.7 to 196.0 ± 117.4 µm (P < 0.001). CVI showed no significant changes, while SA and LA exhibited significant reductions. ONH-MBR and CHOR-MBR decreased (P = 0.004 and P < 0.001, respectively). The baseline SFCT was the only significant predictor of change in CHOR-MBR. Older age correlated with thinner baseline SFCT and a greater decrease in CHOR-MBR.

Conclusions: IVBr is associated with significant reductions in CRT and SFCT and may decrease choroidal blood flow, particularly in older patients and those with thinner SFCTs.

Trial registration: UMIN-CTR Registration ID, UMIN000041382.

抗血管内皮生长因子(VEGF)治疗抑制新生血管性年龄相关性黄斑变性(nAMD)的新生血管形成,但可能减少眼血流量。然而,其与脉络膜厚度的关系尚不清楚。这项研究评估了难治性nAMD患者从玻璃体内注射阿非利塞普或雷尼单抗转为玻璃体内注射布鲁单抗(IVBr)后1个月的结果。方法:本前瞻性单中心研究纳入50例nAMD患者的50只眼。评估最佳矫正视力(BCVA)、视网膜中央厚度(CRT)、中央凹下脉络膜厚度(SFCT)、脉络膜血管指数(CVI)、脉络膜间质面积(SA)、脉络膜腔面积(LA)、视神经头(ONH)平均模糊率(MBR)、脉络膜(CHOR) MBR在切换到IVBr前和1个月后的变化,并用激光散斑血流成像测量血流。进行单因素分析以确定CHOR-MBR变化的潜在预测因素,P变量结果:BCVA维持。CRT从371.6±118.7µm下降到288.8±89.7µm (P)结论:IVBr与CRT和SFCT显著降低相关,并可能减少脉络膜血流量,特别是在老年患者和SFCTs较薄的患者中。试验注册:UMIN-CTR注册号,UMIN000041382。
{"title":"Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration.","authors":"Hirokazu Kojima, Ayana Yamashita, Yuki Nakano, Aki Booka, Yusuke Tatara, Takeyasu Yamada, Junichiro Akimitsu, Yukiko Miyoshi, Rie Osaka, Kiyoshi Suzuma","doi":"10.1007/s40123-025-01279-9","DOIUrl":"10.1007/s40123-025-01279-9","url":null,"abstract":"<p><strong>Introduction: </strong>Anti-vascular endothelial growth factor (VEGF) therapy suppresses neovascularization in neovascular age-related macular degeneration (nAMD) but may reduce ocular blood flow. However, its relationship with choroidal thickness remains unclear. This study evaluated 1-month outcomes after switching from intravitreal aflibercept or ranibizumab to intravitreal brolucizumab (IVBr) in patients with refractory nAMD.</p><p><strong>Methods: </strong>This prospective, single-center study included 50 eyes of 50 patients with nAMD. Changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), choroidal vascularity index (CVI), choroidal stromal area (SA), choroidal luminal area (LA), optic nerve head (ONH) mean blur rate (MBR), and choroidal (CHOR) MBR were evaluated before and 1 month after switching to IVBr, with blood flow measured using laser speckle flowgraphy. Univariate analyses were performed to identify potential predictors of changes in CHOR-MBR, and variables with P < 0.1 were entered into a multiple regression model.</p><p><strong>Results: </strong>BCVA was maintained. CRT decreased from 371.6 ± 118.7 to 288.8 ± 89.7 µm (P < 0.001). SFCT decreased from 231.9 ± 118.7 to 196.0 ± 117.4 µm (P < 0.001). CVI showed no significant changes, while SA and LA exhibited significant reductions. ONH-MBR and CHOR-MBR decreased (P = 0.004 and P < 0.001, respectively). The baseline SFCT was the only significant predictor of change in CHOR-MBR. Older age correlated with thinner baseline SFCT and a greater decrease in CHOR-MBR.</p><p><strong>Conclusions: </strong>IVBr is associated with significant reductions in CRT and SFCT and may decrease choroidal blood flow, particularly in older patients and those with thinner SFCTs.</p><p><strong>Trial registration: </strong>UMIN-CTR Registration ID, UMIN000041382.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"393-402"},"PeriodicalIF":3.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12882904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ophthalmology and Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1